Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Glycemic 100%
• Effectiveness Study 100%
• Liraglutide 100%
• Cardiovascular System 100%
• Cardiovascular Disease 80%
• Treatment Group 80%
• Hazard Ratio 60%
• Congestive Heart Failure 60%
• Myocardial Infarction 40%
• Apoplexy 40%
• Sitagliptin 40%
• Glimepiride 40%
• Glucose 40%
• Morbidity 20%
• Proportional Hazards Model 20%
• Prevalence 20%
• Revascularization 20%
• Cumulative Incidence 20%
• Patient with Type 2 Diabetes 20%
• Cardiovascular Risk 20%
• Glycon 20%
• Unstable Angina Pectoris 20%
• Heart Muscle Revascularization 20%
• Insulin Glargine 20%

Nursing and Health Professions

• Glucose Blood Level 100%
• Liraglutide 100%
• Cardiovascular System 100%
• Maturity Onset Diabetes of the Young 100%
• Cardiovascular Disease 80%
• Treatment Group 80%
• Hazard Ratio 60%
• Congestive Heart Failure 60%
• Heart Infarction 40%
• Rate Ratio 40%
• Cerebrovascular Accident 40%
• Glimepiride 40%
• Sitagliptin 40%
• Glucose 40%
• Patient with Type 2 Diabetes 20%
• Metformin 20%
• Morbidity 20%
• Prevalence 20%
• Proportional Hazards Model 20%
• Heart Muscle Revascularization 20%
• Cardiovascular Risk 20%
• Revascularization 20%
• Insulin Glargine 20%
• Unstable Angina Pectoris 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Effectiveness Study 100%
• Maturity Onset Diabetes of the Young 100%
• Liraglutide 83%
• Cardiovascular Disease 66%
• Treatment Group 66%
• Congestive Heart Failure 50%
• Heart Infarction 33%
• Cerebrovascular Accident 33%
• Sitagliptin 33%
• Glimepiride 33%
• Glucose 33%
• Prevalence 16%
• Morbidity 16%
• Metformin 16%
• Cardiovascular Risk 16%
• Insulin Glargine 16%
• Unstable Angina Pectoris 16%